Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed <i>IDH1/2</i> ‐Mutant Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2 ‐Mutant Acute Myeloid Leukemia

Published:2022-02-14 Issue:4 Volume:11 Page:429-441
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Fan Bin¹,Chen Yue¹,Yin Feng¹,Hua Lei¹,Almon Caroline¹,Nabhan Salah¹,Cooper Michael¹²,Yang Hua¹,Hossain Mohammad¹²

Affiliation:

1. Agios Pharmaceuticals, Inc. Cambridge Massachusetts USA

2. Current address: Servier Pharmaceuticals LLC Boston Massachusetts USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1067

Reference19 articles.

1. IDH mutations in cancer and progress toward development of targeted therapeutics

2. Isocitrate dehydrogenase mutations in myeloid malignancies

3. IDH1andIDH2Mutations in Gliomas

4. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

5. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis;Clinical Epigenetics;2023-07-11

2. Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question;Haematologica;2023-02-01

3. Targeted therapy;Medicines for Cancer;2023